AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.
AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.
This observational study showed that women had a higher risk to develop acute HF after STEMI and women with acute HF after STEMI had a higher mortality rate compared to men.
Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.
Dapagliflozin is now approved by the FDA to reduce the risk of hospitalization for HF in T2DM patients with high CV risk.
CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.
ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.
Prof. Zannad gives an overview of CV outcome trials with SGLT2 inhibitors; first in diabetes patients and now with results in HF patients in the DAPA-HF trial.
Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.
ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.
Changes in NT-proBNP with sacubitril/valsartan therapy were correlated with measures of cardiac function and volume in HFrEF patients in the PROVE-HF trial.
Prof. Wanner highlights challenges in patients with CKD and HF, the effect of SGLT2 inhibitors in these patients and future perspectives.